Marina Talamonti1, Marco Galluzzo1, Andrea Chiricozzi2,3, Pietro Quaglino4, Gabriella Fabbrocini5, Paolo Gisondi6, Angelo Valerio Marzano7,8, Concetta Potenza9, Andrea Conti10, Aurora Parodi11, Stefano Piaserico12, Federico Bardazzi13, Giuseppe Argenziano14, Franco Rongioletti15, Luca Stingeni16, Giuseppe Micali17, Francesco Loconsole18, Maria Teresa Rossi19, Maria Rita Bongiorno20, Claudio Feliciani21, Pietro Rubegni22, Paolo Amerio23, Maria Concetta Fargnoli24, Paolo Pigatto25, Paola Savoia26, Steven Paul Nisticò27, Sandra Giustini28, Andrea Carugno29, Serafinella Patrizia Cannavo'30, Giulia Rech31, Francesca Prignano32, Annamaria Offidani33, Maurizio Lombardo34, Iris Zalaudek35, Luca Bianchi1, Ketty Peris2,3. 1. Dermatology Department, University of Rome "Tor Vergata" , Rome, Italy. 2. Fondazione Policlinico Universitario A. Gemelli IRCCS, Dermatologia, Dipartimento Scienze Mediche e Chirurgiche , Rome, Italy. 3. Università Cattolica del Sacro Cuore, Dermatologia , Rome, Italy. 4. Medical Sciences Department, Dermatologic Clinic, University of Turin , Turin, Italy. 5. Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples, Italy. 6. Section of Dermatology and Venereology, Department of Medicine, University of Verona , Verona, Italy. 7. Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico , Milan, Italy. 8. Department of Pathophysiology and Transplantation, Università Degli Studi di Milano , Milan, Italy. 9. Department of Medico-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi" Sapienza University of Rome - Polo Pontino , Rome, Italy. 10. Dermatologic Unit, Department of Specialized Medicine, AOU Policlinico di Modena , Modena, Italy. 11. Clinica Dermatologica DiSSal Università di Genova, Ospedale-Policlinico San Martino IRCCS Genova , Italy. 12. Dermatology Unit - Department of Medicine DIMED, University of Padova , Padova, Italy. 13. Dermatology Division, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna , Bologna, Italy. 14. Dermatology Unit, University of Campania Luigi Vanvitelli , Naples, Italy. 15. Section of Dermatology, Department of Medical Sciences and Public Health, University of Cagliari , Cagliari, Italy. 16. Dermatology Section, Department of Medicine, University of Perugia , Perugia, Italy. 17. Dermatology Clinic, University of Catania , Catania, Italy. 18. Department of Biomedical Science and Human Oncology, Unit of Dermatology, University of Bari , Bari, Italy. 19. Department of Dermatology, ASST Spedali Civili of Brescia, University of Brescia , Brescia, Italy. 20. Section of Dermatology, Department of Health Promotion, Maternal-Infant, Internal Medicine and Specialization, University of Palermo , Palermo, Italy. 21. Department of Medicine and Surgery, Section of Dermatology, University of Parma , Parma, Italy. 22. Dermatology Unit, Department of Medical, Surgical and Neurosciences, University of Siena , Siena, Italy. 23. Department of Medicine and Aging Science, Dermatologic Clinic, G. D'Annunzio University , Chieti, Italy. 24. Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila , L'Aquila, Italy. 25. Department of Biomedical, Surgical and Dental Sciences, Clinical Dermatology, IRCCS Galeazzi Orthopaedic Institute, University of Milan , Milan, Italy. 26. Department of Health Science, Dermatologic Clinic, University of Eastern Piedmont , Novara, Italy. 27. Dermatology Unit, Department of Health Sciences, Università Magna Graecia , Catanzaro, Italy. 28. Department of Dermatology, 'Sapienza' University of Rome , Rome, Italy. 29. Dermatology Unit, ASST Papa Giovanni XXIII Hospital , Bergamo, Italy. 30. Dermatology, Department of Clinical and Experimental Medicine, University of Messina , Messina, Italy. 31. Division of Dermatology, Santa Chiara Hospital , Trento, Italy. 32. Dermatology Clinic, Department of Health Sciences, University of Florence , Florence, Italy. 33. Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic University of the Marche Region , Ancona, Italy. 34. Unit of Dermatological Diseases, ASST Sette Laghi, Ospedale di Circolo , Varese, Italy. 35. Department of Dermatology, University of Trieste , Trieste, Italy.
Abstract
Background: The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods: Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and undergoing treatment with biologic agents as of 22 February 2020, were eligible to be included in PSO-BIO-COVID study. Demographic and clinical characteristics of patients using any biologic for psoriasis treatment between 22 February and 22 April 2020 were registered. Results: A total of 12,807 psoriatic patients were included in the PSO-BIO-COVID study. In this cohort 26 patients (0.2%) had a swab confirmation of SARS-CoV-2 infection. Eleven patients required hospitalization and two died. Conclusion: The incidence of COVID-19 observed in our cohort of psoriatic patients (0.2%) is similar to that seen in the general population (0.31%) in Italy. However, the course of the disease was mild in most patients. Biological therapies may likely lessen 'cytokine storm' of COVID-19, which sometimes lead to multiple organ failure, ARDS, and death.
Background: The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods: Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and undergoing treatment with biologic agents as of 22 February 2020, were eligible to be included in PSO-BIO-COVID study. Demographic and clinical characteristics of patients using any biologic for psoriasis treatment between 22 February and 22 April 2020 were registered. Results: A total of 12,807 psoriatic patients were included in the PSO-BIO-COVID study. In this cohort 26 patients (0.2%) had a swab confirmation of SARS-CoV-2 infection. Eleven patients required hospitalization and two died. Conclusion: The incidence of COVID-19 observed in our cohort of psoriatic patients (0.2%) is similar to that seen in the general population (0.31%) in Italy. However, the course of the disease was mild in most patients. Biological therapies may likely lessen 'cytokine storm' of COVID-19, which sometimes lead to multiple organ failure, ARDS, and death.
Authors: Thomas Graier; Nicole Golob-Schwarzl; Wolfgang Weger; Theresa Benezeder; Clemens Painsi; Wolfgang Salmhofer; Peter Wolf Journal: Front Med (Lausanne) Date: 2021-02-10
Authors: Joel M Gelfand; April W Armstrong; Stacie Bell; George L Anesi; Andrew Blauvelt; Cassandra Calabrese; Erica D Dommasch; Steven R Feldman; Dafna Gladman; Leon Kircik; Mark Lebwohl; Vincent Lo Re; George Martin; Joseph F Merola; Jose U Scher; Sergio Schwartzman; James R Treat; Abby S Van Voorhees; Christoph T Ellebrecht; Justine Fenner; Anthony Ocon; Maha N Syed; Erica J Weinstein; George Gondo; Sue Heydon; Samantha Koons; Christopher T Ritchlin Journal: J Am Acad Dermatol Date: 2021-01-07 Impact factor: 15.487
Authors: Y Lytvyn; J R Georgakopoulos; A Mufti; A R Devani; M J Gooderham; V Jain; P Lansang; R Vender; V H Prajapati; J Yeung Journal: J Eur Acad Dermatol Venereol Date: 2021-10-28 Impact factor: 9.228
Authors: Andrea Conti; Giovanni Damiani; Roberta Ruggeri; Giulia Odorici; Francesca Farnetani; Paolo Daniele Maria Pigatto; Giovanni Pellacani Journal: Dermatol Ther Date: 2021-08-16 Impact factor: 3.858